<code id='ADE1A2A6CD'></code><style id='ADE1A2A6CD'></style>
    • <acronym id='ADE1A2A6CD'></acronym>
      <center id='ADE1A2A6CD'><center id='ADE1A2A6CD'><tfoot id='ADE1A2A6CD'></tfoot></center><abbr id='ADE1A2A6CD'><dir id='ADE1A2A6CD'><tfoot id='ADE1A2A6CD'></tfoot><noframes id='ADE1A2A6CD'>

    • <optgroup id='ADE1A2A6CD'><strike id='ADE1A2A6CD'><sup id='ADE1A2A6CD'></sup></strike><code id='ADE1A2A6CD'></code></optgroup>
        1. <b id='ADE1A2A6CD'><label id='ADE1A2A6CD'><select id='ADE1A2A6CD'><dt id='ADE1A2A6CD'><span id='ADE1A2A6CD'></span></dt></select></label></b><u id='ADE1A2A6CD'></u>
          <i id='ADE1A2A6CD'><strike id='ADE1A2A6CD'><tt id='ADE1A2A6CD'><pre id='ADE1A2A6CD'></pre></tt></strike></i>

          leisure time

          leisure time

          author:leisure time    Page View:5
          insulin biosimilar
          The suit, filed in a Texas federal court by the American Clinical Laboratory Association and PCR lab HealthTrackRx, claims the FDA does not have the authority to scrutinize lab-developed tests. Jacquelyn Martin/AP

          A group representing clinical labs across the country sued the Food and Drug Administration on Wednesday over the agency’s plan to actively regulate lab-developed tests.

          The suit, filed in a Texas federal court by the American Clinical Laboratory Association and PCR lab HealthTrackRx, claims the FDA does not have the authority to scrutinize lab-developed tests. When the FDA finalized its test regulation plan last month, several experts said it was only a matter of time until someone in the lab industry sued.

          advertisement

          Tests made in labs have historically gone unregulated by the FDA, as the agency considered them low-risk when it started regulating medical devices in 1976. But the tests have since become more numerous and complex, and the regulatory gray area enabled unreliable tests to thrive and harm patients. Infamous examples include Theranos’ blood tests, as well as misleading prenatal genetic tests from a range of companies.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Activists slam private health insurers over coverage restrictions
          Activists slam private health insurers over coverage restrictions

          ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

          read more
          Crowdfunding for medical bills sidesteps core problem, author says
          Crowdfunding for medical bills sidesteps core problem, author says

          AdobeIntheUnitedStates,healthcarecostsaresooutofcontrolthatmedicalcrowdfundinghasbecomecommonplace.T

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          Abbott's new heart device gets FDA advisory panel nod

          ThedeviceiscalledtheTriClip,anditaddressesadiseasecalledtricuspidregurgitation:aheartconditionthatca